Teva completes sale of women’s health business

PhRMA member companies’ R&D spend reaches record $71.4bn
Credit: Shutterstock.com/ nevodka

Teva Pharmaceutical has completed the sale of its global women’s health business to CVC Capital Partners, as announced back in September 2017.

The portfolio, which is marketed and sold outside of the US, includes Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and additional products.

The business will be known as Theramex.

Michael McClellan, Executive Vice President and Chief Financial Officer at Teva, said: “Teva is very pleased to complete the sale of our global women’s health portfolio today, which brings a significant influx of cash needed to further progress our ability to repay term loan debt.

“With the completion of today’s transaction, Teva has generated total proceeds of $2.48 billion from the women’s health divestitures, higher than the previously announced $2.3 billion expected proceeds.”